Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
The research proposed in this application will determine the initial efficacy, safety and
tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a
pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human
laboratory study will be conducted. The proposed study is innovative and important because it
will provide the impetus for the conduct of double blind, placebo-controlled trials to
further demonstrate the efficacy of combined oxazepam and naltrexone for managing
methamphetamine dependence.